Nada Alsuhebany

2.8k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Nada Alsuhebany is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Nada Alsuhebany has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Cardiology and Cardiovascular Medicine and 5 papers in Epidemiology. Recurrent topics in Nada Alsuhebany's work include Chronic Lymphocytic Leukemia Research (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). Nada Alsuhebany is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). Nada Alsuhebany collaborates with scholars based in Saudi Arabia, United States and Sudan. Nada Alsuhebany's co-authors include Abdulkareem Albekairy, Hisham A. Badreldin, Tariq Alqahtani, Shuroug A. Alowais, Sahar S. Alghamdi, Sumaya N. Almohareb, Mohammed Alrashed, Atheer Aldairem, Khalid Bin Saleh and Shmeylan Al Harbi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nada Alsuhebany

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revolutionizing healthcare: the role of artificial intelligence in clinical practice

2023 1.2k citations Shuroug A. Alowais, Sahar S. Alghamdi et al. BMC Medical Education profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nada Alsuhebany Saudi Arabia	7	618	297	283	173	153	25	1.4k
Shmeylan Al Harbi Saudi Arabia	11	617 1.0×	296 1.0×	297 1.0×	176 1.0×	157 1.0×	25	1.5k
Sumaya N. Almohareb Saudi Arabia	4	617 1.0×	294 1.0×	271 1.0×	173 1.0×	137 0.9×	15	1.3k
Mohammed Alrashed Saudi Arabia	4	686 1.1×	368 1.2×	287 1.0×	176 1.0×	150 1.0×	21	1.5k
Shuroug A. Alowais Saudi Arabia	6	685 1.1×	367 1.2×	284 1.0×	177 1.0×	149 1.0×	23	1.5k
Abdulrahman Alshaya Saudi Arabia	9	686 1.1×	368 1.2×	285 1.0×	178 1.0×	167 1.1×	31	1.6k
Khalid Bin Saleh Saudi Arabia	9	685 1.1×	369 1.2×	284 1.0×	176 1.0×	168 1.1×	29	1.6k
Tariq Alqahtani Saudi Arabia	8	686 1.1×	368 1.2×	286 1.0×	176 1.0×	145 0.9×	30	1.6k
Atheer Aldairem Saudi Arabia	3	617 1.0×	294 1.0×	271 1.0×	173 1.0×	137 0.9×	6	1.2k
Majed S. Al Yami Saudi Arabia	12	687 1.1×	367 1.2×	286 1.0×	176 1.0×	151 1.0×	53	1.8k
Hisham A. Badreldin Saudi Arabia	12	689 1.1×	371 1.2×	289 1.0×	183 1.1×	195 1.3×	51	1.9k

Countries citing papers authored by Nada Alsuhebany

Since Specialization

Citations

This map shows the geographic impact of Nada Alsuhebany's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nada Alsuhebany with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nada Alsuhebany more than expected).

Fields of papers citing papers by Nada Alsuhebany

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nada Alsuhebany. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nada Alsuhebany. The network helps show where Nada Alsuhebany may publish in the future.

Co-authorship network of co-authors of Nada Alsuhebany

This figure shows the co-authorship network connecting the top 25 collaborators of Nada Alsuhebany. A scholar is included among the top collaborators of Nada Alsuhebany based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nada Alsuhebany. Nada Alsuhebany is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alsuhebany, Nada, et al.. (2025). Venous thromboembolism prophylaxis practices in hematology/oncology patients admitted to neurological intensive care units. Frontiers in Cardiovascular Medicine. 12. 1573080–1573080.

Alsuhebany, Nada, et al.. (2025). Myocarditis induced by durvalumab in a patient with hepatocellular carcinoma: A case report. Saudi Pharmaceutical Journal. 33(5). 40–40.

Almohareb, Sumaya N., et al.. (2024). Effectiveness of oral antibiotics in managing extended-spectrum B-lactamase urinary tract infections: A retrospective analysis. SAGE Open Medicine. 12. 3932110809–3932110809. 2 indexed citations

Alsuhebany, Nada, et al.. (2024). Characterization of recurrent cytomegalovirus reactivations post allogenic stem cell transplantation in a population with high seropositivity. Virology Journal. 21(1). 149–149.

Badreldin, Hisham A., et al.. (2024). Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition. SHILAP Revista de lepidopterología. 6. 100179–100179. 4 indexed citations

Nguyen, Kelly, et al.. (2024). Evaluation of anti-XA-guided versus APTT-guided management of intravenous unfractionated heparin in patients requiring a durable ventricular assist device. International Journal of Cardiology. 417. 132495–132495.

Badreldin, Hisham A., et al.. (2024). Assessment of cardio-oncology knowledge and practice among healthcare providers in Saudi Arabia: a comprehensive nationwide survey. Cardio-Oncology. 10(1). 93–93. 1 indexed citations

Alsuhebany, Nada, et al.. (2024). Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations. Clinical Medicine Insights Oncology. 18. 1383419501–1383419501. 10 indexed citations

Alowais, Shuroug A., et al.. (2023). Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy. Journal of Oncology Pharmacy Practice. 30(6). 992–998. 3 indexed citations

10.

Alowais, Shuroug A., Sahar S. Alghamdi, Nada Alsuhebany, et al.. (2023). Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 23(1). 689–689. 1238 indexed citations breakdown →

11.

Alsuhebany, Nada, et al.. (2023). Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review. PubMed. Volume 13. 67–76. 4 indexed citations

12.

Alsuhebany, Nada, et al.. (2023). Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. Expert Opinion on Drug Safety. 22(10). 921–928. 11 indexed citations

13.

Saleh, Khalid Bin, Hisham A. Badreldin, Tariq Alqahtani, et al.. (2023). Assessing the influence of COVID-19 on influenza prevalence: A multicenter time series study. Journal of Infection and Public Health. 16(12). 1989–1993. 3 indexed citations

14.

AlZahrani, Abdullah A., et al.. (2023). Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects. Hematology. 29(1). 2296809–2296809. 1 indexed citations

15.

Alsuhebany, Nada, et al.. (2023). Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia. Vaccine. 41(24). 3611–3616. 6 indexed citations

16.

Badreldin, Hisham A., Khalid Bin Saleh, Abdullah A. Alhifany, et al.. (2022). Assessing the Perception of Pharmacy Students on Launching a Doctor of Pharmacy/Master of Public Health Dual Degree Program in Saudi Arabia: A Multi-Institutional Cross-Sectional Study. International Journal of Environmental Research and Public Health. 19(13). 8014–8014.

17.

Alsuhebany, Nada, et al.. (2022). Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling. Journal of the Advanced Practitioner in Oncology. 13(4). 367–378. 2 indexed citations

18.

Svetlov, Maxim S., et al.. (2020). A long-distance rRNA base pair impacts the ability of macrolide antibiotics to kill bacteria. Proceedings of the National Academy of Sciences. 117(4). 1971–1975. 12 indexed citations

19.

Alsuhebany, Nada, et al.. (2018). The Perceptions and Attitudes of Undergraduate Healthcare Sciences Students of Feedback: A Qualitative Study. Health Professions Education. 4(3). 186–197. 13 indexed citations

20.

Almodaimegh, Hind, et al.. (2017). Awareness of venous thromboembolism and thromboprophylaxis among hospitalized patients: a cross-sectional study. Thrombosis Journal. 15(1). 19–19. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact